Compositions for a dietary supplement to manage senescent cells
US-2024390346-A1 · Nov 28, 2024 · US
Pharmaceutical composition for preventing or treating skin cancer comprising Panax spp. plant extract and method of preventing or treating skin cancer in a subject using the same
US10004776B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10004776-B2 |
| Application number | US-201615201819-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 5, 2016 |
| Priority date | Jul 10, 2015 |
| Publication date | Jun 26, 2018 |
| Grant date | Jun 26, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are a pharmaceutical composition for preventing or treating skin cancer and a method of preventing or treating skin cancer in a subject by using the pharmaceutical composition, wherein the pharmaceutical composition includes a Panax spp. plant extract as an active ingredient.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of preventing or treating skin cancer in a subject, the method comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject having skin cancer, wherein the composition comprises a Panax spp. plant extract containing 100% of Rg3, Rk1, and Rg5 with respect to a weight of ginsenoside Rb1, Rc, Rb2, Rd, Rg3, Rk1, and Rg5, and wherein the ratio of Rg3, Rk1, and Rg5 content is 1.42: 1.00: 2.00, and the skin cancer is melanoma. 2. The method of claim 1 , wherein the Panax spp. plant is Panax ginseng, Panax quinquefolia, Panax notoginseng, Panax japonica, Panax trifolia, Panax pseudoginseng, Panax vietnamensis , a cultured root thereof, a heat-treated or enzyme-treated process product thereof, or a combination thereof. 3. The method of claim 1 , wherein the Panax spp. plant extract is a crude extract of water, C1-C4 alcohol, or a mixture thereof of any Panax spp. plant; a solvent fraction of n-hexane, methylenechloride, ethylacetate, butanol, or a mixture thereof of the crude extract; or a purified product of the solvent fraction.
Assignees
Inventors
Classifications
Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine · CPC title
Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title
- A61K36/258Primary
Panax (ginseng) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10004776B2 cover?
- Provided are a pharmaceutical composition for preventing or treating skin cancer and a method of preventing or treating skin cancer in a subject by using the pharmaceutical composition, wherein the pharmaceutical composition includes a Panax spp. plant extract as an active ingredient.
- Who is the assignee on this patent?
- Korea Inst Sci & Tech
- What technology area does this patent fall under?
- Primary CPC classification A61K36/258. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).